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Abstract
Diabetes mellitus type 2 (DM2) patients have higher risk to be infected with parenterally
transmitted viruses, like hepatitis B or C virus. This study aims to determine HBV and HCV
infection prevalence in DM2 patients from Northeast and Southeast Brazil. A total of 537
DM2 patients were included, 194 (36.12%) males and 343 (63.87%) females, with mean
age of 57.13±11.49 years. HBV and HCV markers were determined using serological and
molecular analysis, and risk factors were evaluated in a subgroup from Southeast (n = 84).
Two HBV acute (HBsAg+/anti-HBc -) and one HBV chronic case (HBsAg+/anti-HBc+) were
found. Six individuals (1.1%) were isolated anti-HBc, 37 (6.9%) had HBV infection resolved
(anti-HBc+/anti-HBs+), 40 (7.4%) were considered HBV vaccinated (anti-HBc-/anti-HBs+).
Thirteen patients (2.42%) had anti-HCV and 7 of them were HCV RNA+. In the subgroup,
anti-HBc positivity was associated to age and anti-HCV positivity was associated to age,
time of diabetes diagnosis, total bilirubin, indirect bilirubin, alkaline phosphatase at bivariate
analysis, but none of them was statistically significant at multivariate analysis. As conclu-
sion, low prevalence of HBV and high prevalence HCV was found in DM2 patients.
Introduction
Hepatitis B and C virus infection are major global health problems. All over the world, it has
been estimated that 257 million persons are chronically infected with HBV and 71 million of
individuals are HCV chronic carriers [1,2]. In Brazil, overall prevalence varies from 0 to 16.8%
for Hepatitis B surface antigen (HBsAg) and 1.38% up to 47% for antibodies against HCV
(anti-HCV) according geographic region or specific groups[3–8].
Diabetes mellitus type II (DM2) is a major public health problem in Brazil and is one of the
fastest growing diseases around the world. The International Diabetes Federation estimates
there are now 425 million adults aged 20–79 with diabetes worldwide, including 212.4 million
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who are undiagnosed. In 2045, the estimate is that there are about of 629 million of people
with DM. Currently, Brazil occupies the first place among the countries of South America,
with 13 million individuals with diabetes and occupies the fourth position among the 10 coun-
tries with the highest number of adults with DM2 / territory [9].
According to Brazilian National Household Sample Survey (PNAD), the prevalence of dia-
betes in older individuals has been increased from 10% to 16% in the period of 1998 to 2008 in
Brazil [10].
Liver is the principal site of hormone and glucose metabolism and about 30% of patients
with cirrhosis have diabetes mellitus type 2 [11]. DM2 patients have higher risk to be infected
with parenterally transmitted viruses, like hepatitis B or C virus since they undergo frequent
hospitalization and are submitted to blood tests, like blood glucose monitoring [12].
Hepatitis B infection outbreaks were reported in people/patients with diabetes due to mis-
use of fingerstick devices for monitoring the capillary blood glucose level [13]. HCV infection
also could be transmitted due to frequent exposure to invasive procedures [14].
HCV prevalence in DM2 patients vary from 1.6 to 20.8% according geographical regions
and presence of comorbidities like hemodialysis [12,14,15–17]. Naing et al.[18] observed high
prevalence of diabetes mellitus type 2 in hepatitis C-infected patients compared to uninfected
controls.
A study in China demonstrated higher prevalence of HBV infection (13.5%) in diabetes
mellitus type 2 compared to controls (10.0%) [19]. Indeed, a recent metanalysis of studies
from North America and Asia demonstrated that 8.2% of HBV-infected patients also suffered
from DM2 [20].
In Brazil, anti-HCV prevalence varied from 2 to 7% in DM patients from Central West and
South region of Brazil [21–23] while DM2 was observed in 10.3% of renal transplant patients
infected with HBV in Brazil [24]. At this moment, little is known about the prevalence of these
viruses in other regions of Brazil, the risk factors related to HBV and HCV positivity, HBV
and HCV viremia and genotypes in these individuals. The objectives of this study were to esti-
mate the seroprevalence rates of hepatitis B and C in DM2 patients from Northeast and South-
east regions of Brazil, to explore the risk factors for hepatitis in a sub group of DM2 patients
from Southeast region (Rio de Janeiro State) and to determine HBV and HCV viremia.
Material and methods
Population studied
This was a cross-sectional study on DM2 patients recruited during 2007–2013 at two geo-
graphical regions in Brazil (Southeast and Northeast Region). Patients were recruited at endo-
crinology outpatient units in Federal University of State of Rio de Janeiro (UNIRIO-Rio de
Janeiro) (n = 84) (Group 1) and from Brazilian Metabolic Syndrome Study (BRAMS), a multi-
center survey, which included individuals from three different States in Brazil: Ceará (North-
east region), São Paulo and Minas Gerais (Southeast region) (n = 453) (Group 2). The subjects
who were invited to participate were selected from outpatient clinics for the metabolic syn-
drome and obesity or through local and internet advertisements.
In this study, samples were selected using an intentional non-probabilistic sampling. A total
of 537 DM2 patients were enrolled, 194 (36.12%) males and 343 (63.87%) females, with a
median age of 57 years, ranged 29–89 years old. Data such as gender and age were collected
from the clinical records of each patient from individuals from Ceará, Minas Gerais and São
Paulo State. From Rio de Janeiro State, it was administered a questionnaire to collect informa-
tion concerning gender, age, education level and risk factors for viral hepatitis such as sexual
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behavior and practices, occupational exposure, parenteral exposure to blood on previous
transfusion, surgery, intravenous drug use and needle sharing.
The criteria for enrollment for both groups were diagnosis of DM if there was documented
use of oral hypoglycemic medication or insulin or according to the American Diabetes Associ-
ation criteria with random glucose more than 200 mg/dL, or fasting glucose greater than 126
mg/dL on two occasions. The exclusion criteria for both groups were the evidence of hepato-
cellular carcinoma and absence to consent.
The study protocol was carried out in accordance with the Declaration of Helsinki and was
approved by the Ethics Committee of Oswaldo Cruz Foundation, Campinas University and
Federal University of Rio de Janeiro State under the numbers of CAAE: 24930813.0.0000.5248;
24930813.0.3002.5404; 24930813.0.3001.5258.
All participants were given a verbal explanation of the objectives and methodology of the
research and were included in the study after obtaining signed informed consent. All individu-
als who tested positive were sent to public health units to had access to treatment.
Laboratory tests
Blood sample was obtained by venipuncture before the attendance at outpatient clinics. Serum
samples from all individuals of the study were tested for HBsAg, anti-HBc, anti-HBs, anti-
HCV using commercial eletrochimioluminescence assay (ECLIA) (Roche, USA) according to
the manufacturer’s guidelines. Samples found to be negative on the preliminary screening
were considered seronegative. Samples that initially tested borderline or positive were retested
using ECLIA to confirm the results.
Serum aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase
[AST]), gamma-glutamyltransferase (GGT), phosphatase alkalin, total cholesterol, high-den-
sity lipoprotein (HDL) and low-density lipoprotein cholesterol (LDL), triglycerides and
plasma glucose were measured with an automatic analyzer (Labmax 240 Premium, Labtest,
Minas Gerais, Brazil). ALT, AST, GGT and glucose were determined in all individuals while
these biochemical data, complete blood count, phosphatase alkalin, cholesterol, HDL choles-
terol, Triglycerides, Bilirrubin total, direct and indirect were determined only from individuals
from Rio de Janeiro State.
Serum HCV RNA and HBV DNA was detected in anti-HCV and HBsAg positive samples
using a standardized automated quantitative assay (COBAS TaqMan HCV Test and HBV
Test, Roche, Branchburg, NJ, USA) and expressed as IU/mL. The limit of detection is 3.5 IU/
mL and 18IU/mL for serum by PROBIT analysis for COBAS TaqMan HBV Test and HCV
Test, respectively.
Data collection and analysis
Data are expressed as frequencies and mean with standard deviation. Bivariate analysis was
performed using the chi-square (x2) test for independence with Yate’s continuity correction,
x2 for trend and Fisher’s exact test when appropriate to compare proportions. Student’s t-test
was used to analyse normally distributed quantitative variables and non-parametric (Mann-
Whitney U test) statistics was used to analyse quantitative variables, which did not pass nor-
mality test (Kolmogorov-Smirnov test). Variables selected for their statistical significance
(P< 0.05) in the bivariate analysis were entered the multiple logistic regression model in a
stepwise fashion. Estimated odds ratio (OR) were also calculated. All calculations, including
multiple logistic regression analysis (MLR), were undertaken by using the Statistical Package
for the Social Sciences (SPSS for Windows, release 20.0; SPSS, Inc., Chicago, IL, USA).
HBV and HCV in diabetes type 2
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Results
HBV and HCV markers in population studied
Among the 537 DM2 patients, 3 patients (0.55%) had HBsAg but no one had HBV DNA, 44
(8.19%) had previous contact to HBV (anti-HBc reactive), 77 (14.33%) were immune to HBV
(anti-HBs reactive). In the group of HBV immune individuals, 40 (7.44%) were vaccinated (only
anti-HBs reactive). Thirteen individuals (2.42%) had anti-HCV and seven of them were HCV
RNA positive. One individual was HBsAg and anti-HCV reactive. A total of 452 individuals
(84.17%) were seronegative for all HBV markers, but 8 of them were anti-HCV reactive. Age,
gender and laboratory data from total population and groups 1 and 2 are presented in Table 1.
In group 1, high mean±SD age (64.90±10.24 years) and females (73.8%) were predominant.
Previous HBV infection and HBV immunity were more frequent in this group as determined
by anti-HBc (19.04%) and anti-HBs (29.76%) positivity, respectively. Anti-HCV prevalence
was high in group 1 (7.14%), although only 2 were HCV RNA reactive.
Among group 2 (individuals from Minas Gerais, Ceará and São Paulo State), 172 (37.96%)
males and 281 (62.03%) females and mean±SD age of 55.68±11.12 years. In this group, 3 had
HBsAg, 28 were anti-HBc reactive, 52 were anti-HBs reactive, 7 were anti-HCV reactive and 5
out 7 were HCV RNA reactive. High mean values of AST, ALT, GGT and blood glucose was
observed in this group compared to group 1.
Demographic and risk factor characteristics in group 1
The socio-demographic characteristics and risk factors of the 84 individuals with diabetes
from Rio de Janeiro are shown in Table 2. Most of participants in this study were females
Table 1. Demographic, laboratory, HBV and HCV markers in type 2 diabetes mellitus patients recruited in groups 1 and 2.
Variable Total Population
(n = 537)
Group 2 (n = 453) Group 1 (n = 84)
Age, years (mean±SD) 57.13±11.49 55.68±11.12 64.9±10.24
Gender, Male/Female (n) 194/343 172/281 22/62
Platelet Count x 103/mm, (mean±SD) 206.60±47.99 ND 206.60±47.99
ALT, IU/L, (mean±SD) 25.18±26.26 26.76±27.37 14.56±12.72
AST, IU/L, (mean±SD) 22.57±13.20 23.24±12.93 17.92±14.23
Phosphatase alkaline, IU/L, (mean±SD) 64.90±27.33 ND 64.90±27.33
GGT, IU/L, (mean±SD) 42.87±40.00 44.53±41.39 31.14±25.63
Cholesterol, mg/dL, (mean±SD) 187.77±49.15 ND 187.77±49.15
HDL cholesterol, mg/dL, (mean±SD) 42.49±11.12 ND 42.49±11.12
Triglycerides, mg/dL, (mean±SD) 133.16±56.14 ND 133.16±56.14
Total Bilirubin, ng/mL, (mean±SD) 0.09±0.08 ND 0.09±0.08
Indirect Bilirubin, ng/mL, (mean±SD) 0.01±0.10 ND 0.01±0.10
Direct Bilirubin, ng/mL, (mean±SD) 0.11±0.09 ND 0.11±0.09
Blood glucose, ng/mL, (mean±SD) 153.72± 66.28 158.68±66.85 126.62±56.13
Haemoglobin, (mean±SD) 12.72±1.81 ND 12.72±1.81
HBsAg reactive, n (%) 3 (0.55) 3 (0.66) 0 (0.00)
Anti-HBc reactive, n (%) 44 (8.19) 28 (6.18) 16 (19.04)
Anti-HBs reactive, n (%) 77 (14.33) 52 (11.47) 25 (29.76)
Anti-HBs titer, IU/mL, (mean±SD) 183.30±272.36 69.07±35.72 407.51±379.53
Anti-HCV, n (%) 13 (2.42) 7 (1.54) 6 (7.14)
ND: not done
https://doi.org/10.1371/journal.pone.0211193.t001
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(73.8%), married (52.38%), had preschool (36.90%), received from 294.78–884.38 US dollars,
had mean age of 64.99±10.24 years and more than 10 years of diabetes diagnosis (48.80%).
Thirteen individuals reported a previous history of hepatitis, and six reported HBV vaccina-
tion. Regarding risk factors, only two were under hemodialysis and one had tattoo. Fourteen
individuals had received a blood transfusion, 8 of which were received before 1994. Most of
these individuals visited manicurists (69.04%), but 16 of them (27.3%) used their own nail
Table 2. Demographic and risk factors related to anti-HBV antibodies (total anti-HBc and anti-HBs) and anti-HCV positivity among person with diabetes in
group 1 (n = 84).
Items Total n = 84 (%) Anti-HBc positive n = 16 (%) Anti-HBs positive n = 25 (%) Anti-HCV positive n = 06 (%)
Age, mean±SD 64.99±10.24 67 64 56
Gender, Female/Male 62/22 10/6 19/6 5/1
Marital Status, married 44 (52.38) 10 (62.5) 13 (52.00) 2 (33.33)
Scholarity
Illiterate
4 (4.76) 0 (0.0) 0 (0.00) 0 (0.00)
Pre-school 31 (36.90) 13 (81.25) 12 (48.00) 1 (16.66)
Primary School 28 (33.33) 3 (18.75) 8 (32.00) 3 (50.00)
Secondary School 15 (17.85) 0 (0.0) 1 (4.00) 1 (16.66)
College 6 (7.14) 0 (0.0) 3 (12.00) 1 (16.66)
Family Income
Nothing
2 (2.38) 1 (6.25) 1 (4.00) 0 (0.00)
U$S 294.78–884.38 35 (41.66) 8 (50.0) 12 (48.00) 2 (33.33)
More than U$S 884.38 9 (9.52) 1 (6.25) 3 (12.00) 1 (16.66)
Dark urine and hepatitis confirmed 13 (15.47) 4 (25.00) 6 (24.00) 3 (50.00)
HBV Vaccine 06 (7.14) 0 (0.00) 3 (12.00) 1 (16.66)
Blood transfusion 14 (16.66) 5 (31.25) 7 (28.00) 3 (50.00)
Haemodialysis 02 (2.38) 0 (0.00) 1 (4.00) 1 (16.66)
Acupuncture 18 (21.42) 2 (12.5) 6 (24.00) 1 (16.66)
Sharing razors/blade 07 (8.33) 1 (6.25) 3 (12.00) 0 (0.00)
Sharing Toothbrushes 15 (17.85) 3 (18.75) 6 (24.00) 3 (50.00)
Venous access 69 (82.14) 14 (87.5) 20 (80.00) 5 (83.33)
Manicure 58 (69.04) 10 (62.5) 18 (72.00) 4 (66.66)
Number of sexual partners
Regular
43 (51.19) 5 (31.25) 13 (52.00) 5 (83.33)
Less than 5 28 (33.33) 7 (43.75) 7 (28.00) 1 (16.66)
No sexual partner 13 (15.47) 4 (25.00) 5 (20.00) 0 (0.00)
Condom usage
Rarely 11 (13.09) 3 (18.75) 3 (12.00) 1 (16.66)
Never 50 (59.52) 7 (43.75) 12 (48.00) 3 (50.00)
Always 6 (7.14) 1 (6.25) 3 (12.00) 1 (16.66)
Oral sexual intercourse 33 (39.28) 6 (37.5) 7 (28.00) 3 (50.00)
Anal sexual intercourse 13 (15.47) 3 (18.75) 4 (16.00) 3 (50.00)
Contact with person with hepatitis 21 (25.00) 0 (0.00) 0 (0.00) 1 (16.66)
Infection Sexually transmitted (IST) 14 (16.66) 6 (37.5) 5 (31.25) 0 (0.00)
Drinking alcohol 16 (19.04) 3 (18.75) 7 (28.00) 1 (16.66)
Time of Diabetes diagnosis
<1 year 03 (3.57) 0 (0.00) 1 (4.00) 2 (33.33)
1–5 years 21 (25.00) 3 (18.75) 7 (28.00) 0 (0.00)
5–10 years 15 (17.85) 4 (25.00) 6 (24.00) 0 (0.00)
>10 years 41 (48.80) 9 (56.25) 10 (40.00) 3 (50.00)
https://doi.org/10.1371/journal.pone.0211193.t002
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plier. Most of individuals had history of venous access (82.14%) and no one reported drug use.
Regarding sexual orientation, 76 (90.47%) of these individuals were heterosexual, 1 (1.19%)
was bisexual and 07 (8.33%) did not informed. Forty-three (51.19%) had a regular partner, 61
(63.0%) individuals never or rarely used condoms during sexual intercourse, 33 (39.28%)
reported engaging in oral sex and 13 (15.47%) in anal sex, 14 (16.66%) had a history of IST,
and four (4.76%) had a sexual partner infected with HIV or viral hepatitis.
Demographic and laboratorial data according HCV infection in group 2
Anti-HCV positivity was evaluated regarding gender, age, and biochemical characteristics
(Table 3). In this group, high mean values of GGT, AST, ALT were found among HCV reactive
individuals. In addition, anti-HCV cases were from São Paulo and Ceará States (Southeast and
Northeast region). Anti-HCV was associated to ALT values in bivariate analysis (p = 0.017).
HBV and HCV prevalence and risk factors in group 1
Anti-HBc and anti-HBs prevalences were 19.04% and 29.76%, respectively. Thirteen individu-
als (15.47%) were HBV vaccinated, 12 (14.3%) individuals were resolved HBV infection and
four were anti-HBc isolated (4.8%). Using anti-HBc as dependent variable in bivariate analysis,
only age was statistically significant.
In group 1, anti-HCV prevalence was 7.14%. In bivariate analysis, anti-HCV positivity was
associated with age, time of diabetes diagnosis, total bilirubin, indirect bilirubin, alkaline phos-
phatase, but none of them was found to be statistically significant in the multivariate analyses
(Table 4).
Discussion
This study showed prevalence rates of HBsAg and anti-HCV in DM2 patients of 0.55% and
2.42%, respectively. HBsAg prevalence was low compared to studies among DM patients in
Table 3. Bivariate analysis of factors associated to anti-HCV positivity in group 2.









Glucose (mg/dL), (mean±SD) 158.89 ±67.05 146.14±56.11 0.612
Insulin (μU/mL), (mean±SD) 15.48 ±19.85 10.19 ±7.70 0.181
GGT (IU/L), (mean±SD) 44.05 ±41.04 75.57 ±54.98 0.057
AST (IU/L), (mean±SD) 23.15±12.86 29.14 ±17.31 0.167
ALT (IU/L), (mean±SD) 26.57 ±27.49 39.14 ±15.24 0.017
PCR, (mean±SD) 0.55 ±0.79 0.14 ±0.12 0.141
State of Brazil 0.064
Ceará 240 03
Minas Gerais 120 00
São Paulo 86 04
NA: Not available.
Values in bold indicate significant values (p < 0.05).
https://doi.org/10.1371/journal.pone.0211193.t003
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China (13.5%) [19], Gana (5.5%) [25] and Ethiopia (3.7%) [26], but similar prevalence was
reported in general population in Brazil [3,6] suggesting that DM2 patients is not at higher
risk to infection by HBV than the general population in this region. In addition, no individual
had HBV DNA detected in HBsAg positive samples what could be the result of HBV treatment
at the time of collection or transportation of samples from distinct regions from Brazil to
Southeast region where molecular assays were conducted.
A total of 14.33% of DM2 individuals were immune to HBV (anti-HBs reactive) as it was
found in DM2 patients from Southeast region of Brazil (13.7%) [27]. The importance of HBV
vaccination in diabetes patients is not much disseminated, although public health policies rec-
ommend vaccination through educational campaigns to patients and public health profession-
als. In 2016, HBV vaccination was extended to all age groups in public health units what could
increase the burden of vaccinated individuals in near future.
In group 2, prevalence of anti-HBc and anti-HBs were higher compared to group 1. How-
ever, anti-HBs prevalence was still lower than found in Chronic kidney disease (CKD) patients
at Northeast region [7] and HIV/HCV infected individuals from Southeast region [28] demon-
strating that prevention programs for HBV vaccination should be increase in DM2 patients.
Anti-HBc presence was high among older groups showing statistical significance as found in
CKD patients, beauticians and general population in Brazil [3,6,7]. The finding of age as a sig-
nificant variable is probably observed due to the implementation of compulsory vaccination in
younger groups in Brazil.
Considering total population, high anti-HCV prevalence (2.42%) was found as the same as
demonstrated in DM2 patients from Central West region of Brazil (2 to 2.6%) [21,22], but
lower than found in DM2 patients from South region of Brazil (12.9%) [23]. High anti-HCV
prevalence was found in group 1 (7.14%) compared to group 2 (1.54%) what could be the
reflect of different settings of recruitment or the high frequency of venous access reported by
group1 what could be the result of insulin administration in emergency situations, since more
than 56% of individuals that reported venous access had more than 10 years of diagnosis of
diabetes. We did not know if this venous access was made under universal precaution what
could explain the high HCV prevalence in this group. Studies conducted in DM2 patients
from Taiwan (6.8%) [29] and Egypt (18%) [17] also observed high anti-HCV prevalence prob-
ably due to parenteral exposures from reused needles for vaccinations in these countries.
Anti-HCV reactivity was associated to ALT values in group 2. Korkmaz et al.[30] showed
elevated prevalence of HBV and HCV in DM2 patients with increased compared to normal
aminotransferase levels (23.1% versus 2.3% for HBV and 19.2% versus 2.0%). In the same
Table 4. Bivariate and multivariate analysis of demographic and laboratorial data associated with anti-HCV prevalence in group 1.









Age, years,mean±SD 42.1 ±10.4 35.2 ±12.3 0.028 0.345 0.998
Time of diabetes diagnosis 1.000
<1 year 2 1 0.007 2.485
1–5 years 0 21 36499.1
5–10 years 0 15 0.000
>10 years 3 38 0.000
Total Bilirubin, ng/mL, mean±SD 0.24 ±0.10 0.09 ± 0.08 0.003 0.000 1.000
Indirect Bilirubin, ng/mL, mean±SD 0.13 ±0.03 0.02 ± 0.10 0.010 1.340 0.998
Alkaline Phosphatase, IU/L, mean±SD 124 ± 00 63 ±25.56 0.001 1.947 0.996
https://doi.org/10.1371/journal.pone.0211193.t004
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group, anti-HCV was not associated to local of residence, although there were not HCV
infected individuals from Minas Gerais State (Southeast region).
Anti-HBc and anti-HCV positivity were not associated to risk factors, like history of blood
transfusion, sharing razors, hemodialysis and sexual habits in contrast to other studies
[15,16,30,31]. On the other hand, anti-HCV seropositivity was associated to high mean age
and high mean values of alkaline phosphatase, indirect bilirubin and total bilirubin. Ocak et al.
[16] also demonstrated that age was related to HCV seropositivity among DM2 patients on
haemodialysis. In this group, individuals were not previously HCV diagnosed cases, but they
could have some liver disfunction, like cirrhosis, since bilirubin and alkaline phosphatase ele-
vations were found in this group and associated to anti-HCV positivity. Unfortunately, no
information regarding cirrhosis was obtained in this group.
Diabetes duration over 5 years increased the risk of’ HCV infection in the present study as
the same as demonstrated among DM2 patients in Saudi Arabia [12]. A long duration of dia-
betes may lead to the performance of more medical interventions, like exposure to venous
access during emergency situations, and may increase the risk of HCV infection.
In this study, most of DM2 patients also presented HCV viremia what could increase the
risk of hepatic steatosis, fibrosis and hepatocarcinoma. In addition, these disorders associated
with metabolic syndrome, independently increase the risk of cardiovascular and cerebrovascu-
lar disease and mortality [32].
This study presents some limitations, such as, the small number of individuals in group 1
for multivariate analysis, absence of information regarding hospitalization and comorbidities
and absence of risk factors information and previous HBV treatment in group 2. The design of
the study (cross sectional study) cannot demonstrate cause and effect, but it can be used to
prove and/or disprove assumptions; captures a specific point in time; contains multiple vari-
ables at the time of the data snapshot and the findings and outcomes can be analyzed to create
new theories/studies or in-depth research.
In conclusion, low prevalence of HBV and high prevalence of HCV were observed in DM2
patients.
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